Abstract

The Administrative Core will provide support for all three Projects, as well as scientific Core B.
The aims of the Administrative Core are to ensure and facilitate equitable distribution of resources through the.Program Project. In addition, this core will also ensure compliance with National Cancer Institute and National Institutes of Health rules and regulations. The Administrative Core will coordinate weekly research-ln-progress meetings, attended by Project Leaders and their laboratories. The Core will also coordinate weekly Core B meetings, which will function to prioritize sample processing and analysis. The Administrative Core will also function to coordinate communication between Program Project members and our External Advisory Board. Dr. Koumenis will be Core Director and will be supported by Ms. Dona Zlkowltz. Ms. Zikowitz will also provide administrative support for each of the Program Leaders and coordinate travel when External Advisory Board members travel to the University of Pennsylvania. Finally, Ms. Zikowitz will interface with grants management personnel within Department of Radiation Oncology and the Abramson Cancer Center, where this Program Project will be administered

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
4P01CA165997-04
Application #
9122099
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
4
Fiscal Year
2016
Total Cost
Indirect Cost

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Bu, Yiwen; Yoshida, Akihiro; Chitnis, Nilesh et al. (2018) A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nat Cell Biol 20:104-115
Nguyen, Hao G; Conn, Crystal S; Kye, Yae et al. (2018) Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med 10:
Zhao, Bin; Bhattacharya, Sabyasachi; Yu, Qiujing et al. (2018) Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leuk Lymphoma 59:171-177
Hong, Feng; Liu, Bei; Wu, Bill X et al. (2017) CNPY2 is a key initiator of the PERK-CHOP pathway of the unfolded protein response. Nat Struct Mol Biol 24:834-839
Rozpedek, W; Nowak, A; Pytel, D et al. (2017) Molecular Basis of Human Diseases and Targeted Therapy Based on Small-Molecule Inhibitors of ER Stress-Induced Signaling Pathways. Curr Mol Med 17:118-132
Ortiz, Angélica; Fuchs, Serge Y (2017) Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine 89:4-11
Katlinski, Kanstantsin V; Gui, Jun; Katlinskaya, Yuliya V et al. (2017) Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 31:194-207
Katlinskaya, Yuliya V; Katlinski, Kanstantsin V; Yu, Qiujing et al. (2016) Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep 15:171-180
Truitt, Morgan L; Ruggero, Davide (2016) New frontiers in translational control of the cancer genome. Nat Rev Cancer 16:288-304
Bu, Yiwen; Diehl, J Alan (2016) Stressing out melanoma with an anti-GRP78 compound. Pigment Cell Melanoma Res 29:490-1

Showing the most recent 10 out of 28 publications